Gilead Sciences : GILD

All Gilead Sciences Articles

730 Articles

Trey Thoelcke | May 10, 2014 at 10:00 AM EDT

The Six Most Shorted Stocks on the Nasdaq

courtesy of Sirius XM RadioShort sellers continue to hold huge positions not only in troubled companies like BlackBerry Ltd. (NASDAQ:…

Jon C. Ogg | May 8, 2014 at 8:35 AM EDT

RBC Doctor Panel Picks in Drugs and Biotech

In a new research report, the pharmaceutical and biotech analysts at RBC highlight their meetings with a group of six…

Trey Thoelcke | Apr 27, 2014 at 10:05 AM EDT

The Eight Most Shorted Stocks on the Nasdaq

bfishshadow via Wikimedia CommonsShort sellers continue to hold huge positions not only in troubled companies like BlackBerry and Staples, but…

cgblaine22 | Apr 26, 2014 at 8:30 AM EDT

Biotech: The Poster Child for Market Volatility in 2014

The NYSE Arca Biotechnology Index fell nearly 9% between a peak on Jan. 22 and a low on Feb. 5.…

Jon C. Ogg | Apr 23, 2014 at 3:35 PM EDT

Why Investors Are Not Chasing Gilead Endlessly Higher

ThinkstockBy any stretch of normal measurement in earnings season, Gilead Sciences Inc. (NASDAQ: GILD) should have been a rocketing stock…

Jon C. Ogg | Apr 23, 2014 at 10:50 AM EDT

Companies Betting on the Next 10 Blockbuster Drugs

24/7 Wall St. wanted to evaluate the prospects for several would-be blockbuster drugs. Some of these have approvals already in…

Jon C. Ogg | Apr 23, 2014 at 8:50 AM EDT

UBS Top Stocks to Buy Working for Cancer Cures

In a new research report, the Healthcare team at UBS took an in-depth look at the top companies that are…

Jon C. Ogg | Apr 22, 2014 at 4:48 PM EDT

An Earnings Tale of Two Biotechs: Gilead vs. Amgen

ThinkstockGilead Sciences Inc. (NASDAQ: GILD) and Amgen Inc. (NASDAQ: AMGN) have both reported earnings. This is a definite difference in…

Jon C. Ogg | Apr 22, 2014 at 12:00 PM EDT

Biotech Earnings Previews: Amgen, Biogen Idec, Gilead, Celgene

ThinkstockBiotech stocks took it on the chin during the sell-off. In fact, biotech stocks may have even led the sell-off…

Trey Thoelcke | Apr 21, 2014 at 9:05 AM EDT

J.P. Morgan’s Top Biotech and Health Care Picks With Huge Upside

In a new research report, the J.P. Morgan health care team highlights their top names to buy after the sell-off…

Paul Ausick | Apr 11, 2014 at 4:01 PM EDT

The 4 Stocks That Sank the Market

thinkstockApril 11, 2014: Markets opened lower on Friday with the S&P 500 and the Nasdaq Composite breaking into positive territory…

Trey Thoelcke | Apr 11, 2014 at 9:50 AM EDT

Five Stocks That Have Fallen Most With the Lowest P/E Ratios

In a new report, RBC has a list of stocks with some of the largest percentage drops and the lowest…

Jon C. Ogg | Apr 10, 2014 at 11:33 AM EDT

Gilead Risks Beyond Just Merck: Serious Chart Violation Watch

Gilead Sciences may have been largely responsible for the drop in biotech stocks after politicians went after its drug costs,…

Trey Thoelcke | Apr 10, 2014 at 8:00 AM EDT

Who Bucked the Short Interest Trend in Biotech Stocks?

Thinkstock24/7 Wall St. has tracked the short interest in leading biotech and emerging pharmaceutical stocks. Many biotech stocks pulled back…

Trey Thoelcke | Apr 8, 2014 at 8:40 AM EDT

Deutsche Bank Big Cap Stock Picks With Low P/E Ratios

The recent violent sell-off has unnerved investors and given the bears the floor for the first time in a while.…

1 … 36 37 38 39 40 … 49

Gilead Sciences : GILD

All Gilead Sciences Articles

The Six Most Shorted Stocks on the Nasdaq

RBC Doctor Panel Picks in Drugs and Biotech

The Eight Most Shorted Stocks on the Nasdaq

Biotech: The Poster Child for Market Volatility in 2014

Why Investors Are Not Chasing Gilead Endlessly Higher

Companies Betting on the Next 10 Blockbuster Drugs

UBS Top Stocks to Buy Working for Cancer Cures

An Earnings Tale of Two Biotechs: Gilead vs. Amgen

Biotech Earnings Previews: Amgen, Biogen Idec, Gilead, Celgene

J.P. Morgan’s Top Biotech and Health Care Picks With Huge Upside

The 4 Stocks That Sank the Market

Five Stocks That Have Fallen Most With the Lowest P/E Ratios

Gilead Risks Beyond Just Merck: Serious Chart Violation Watch

Who Bucked the Short Interest Trend in Biotech Stocks?

Deutsche Bank Big Cap Stock Picks With Low P/E Ratios

Mark Cuban’s Dire Prediction: Could These Trade Policies Trigger a Recession Worse Than 2008?

XRP Price: XRP ETFs Snapped Their Longest Inflow Streak of 2026 as Price Slips Below $1.40

Jim Cramer to Brinker’s CEO: How Do You Make More Money When Every Cost Is Going the Wrong Way?

Retirees Are Realizing a $1.5 Million Nest Egg at 60 Only Means $31,000 in Real Annual Spending

71% of Americans With Financial Advisors Feel Secure. Only 10% Without One Do

Mark Cuban’s Dire Prediction: Could These Trade Policies Trigger a Recession Worse Than 2008?

XRP Price: XRP ETFs Snapped Their Longest Inflow Streak of 2026 as Price Slips Below $1.40

Gilead Sciences : GILD

All Gilead Sciences Articles

The Six Most Shorted Stocks on the Nasdaq

RBC Doctor Panel Picks in Drugs and Biotech

The Eight Most Shorted Stocks on the Nasdaq

Biotech: The Poster Child for Market Volatility in 2014

Why Investors Are Not Chasing Gilead Endlessly Higher

Companies Betting on the Next 10 Blockbuster Drugs

UBS Top Stocks to Buy Working for Cancer Cures

An Earnings Tale of Two Biotechs: Gilead vs. Amgen

Biotech Earnings Previews: Amgen, Biogen Idec, Gilead, Celgene

J.P. Morgan’s Top Biotech and Health Care Picks With Huge Upside

The 4 Stocks That Sank the Market

Five Stocks That Have Fallen Most With the Lowest P/E Ratios

Gilead Risks Beyond Just Merck: Serious Chart Violation Watch

Who Bucked the Short Interest Trend in Biotech Stocks?

Deutsche Bank Big Cap Stock Picks With Low P/E Ratios

Mark Cuban’s Dire Prediction: Could These Trade Policies Trigger a Recession Worse Than 2008?

XRP Price: XRP ETFs Snapped Their Longest Inflow Streak of 2026 as Price Slips Below $1.40

Jim Cramer to Brinker’s CEO: How Do You Make More Money When Every Cost Is Going the Wrong Way?

Featured Reads

Retirees Are Realizing a $1.5 Million Nest Egg at 60 Only Means $31,000 in Real Annual Spending

71% of Americans With Financial Advisors Feel Secure. Only 10% Without One Do